Management of abnormal cytology results and correlation of cytopathologic results accompanied by colposcopy in our clinic.
Abstract
Aim: Pap smear test is a major screening test for early diagnosis and treatment of cervix cancer. The aim of our study was to assess the value of colposcopy and histopathologic examination in the management of patients with abnormal cervical cytology by Bethesda Classification.
Methods: In this study, we aimed to compare and evaluate the diagnosis of 12,381 cytology material examined in our gynecology clinic during the years between 2014 and 2016 with their cytopathology results.
Results: 498 of 12,381 patients had abnormal cytological findings (4.02%). The rates of Atypical Squamous Cells of Undetermined Significance (ASC-US), Atypical Glandular Cells of Undetermined Significance (AG-US), Low Grade Squamous Intraepithelial Lesions (LG-SIL) and High Grade Squamous Intraepithelial Lesions (HG-SIL) were found to be 1.9%, 0.4%, 1% and % 0.1, respectively. Atypical squamous cell cannot exclude HSIL (ASC-H) rate were found as % 0.4. The rate of abnormal cytology in cervical intraepithelial lesions was 2.1. Positive predictive values of abnormal smear results were 21.7% for ASC-US, 41.9% for LGSIL, 100% for HGSIL, 12.5% for AGUS and 50% for ASC-H.
Conclusion: The Pap smear test is a cheap and easily applied screening test. Early diagnosis of cervix cancer can be made by routine Pap smear testing. The efficiency in clinical use of the cervical cytology screening test is determined by biopsy verification. As the ratio of epithelial cell abnormality is variable in different populations, the ASC (Atypical Squamous Cell) / SIL (Squamous Intraepithelial Lesion) is a more definite variable to be used for quality assurance.
Keywords
Kaynakça
- 1. Aslan D. Contemporary problems in public medicine and approaches. Ankara Tabib Odası 2009; 25-45.
- 2. Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
- 3. Ozgul N. Current state of cervical cancer and cervical cancer screening in Turkey. In: Tuncer AM, editor. Cancer control in Turkey. 1st ed. Ankara: 2007. pp. 349–58.
- 4. Nanda K, McCrory DC, Myers ER, . Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 2000 May 16;132(10):810-9
- 5. Saslow D, Runowicz CD, Solomon D, Moscicki AB, Smith RA, Eyre HJ, et al; American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 2002 Nov-Dec;52(6):342-62.
- 6. Kuo DY, Goldberg GL. Screening of cervical cancer: where do we go from here? Cancer Invest 2003; 21(1): 157–161.doi:10.1081/CNV-120016410.
- 7. Benedet J, Matisic J, Bertrand M. An analysis of 84,244 patients from the British Columbia cytology–colposcopy program: Gynecologic Oncology 2004;92(3):127–134.
- 8. Rock JA, Jones HW: Te Linde’s Operative Gynecology, Dokuzuncu Basım, Lippincott Williams & Wilkins Yayınları , Servikal Kanser Prekürsörleri ve Yönetimi, Bölüm 45-46; 1231-1254.
Ayrıntılar
Birincil Dil
İngilizce
Konular
Cerrahi
Bölüm
Araştırma Makalesi
Yazarlar
Ozan Doğan
Department of Obstetrics and Gynecology, Sisli Hamidiye Etfal Research and Training Hospital,Istanbul, Turkey
Türkiye
Ahmet Yıldız
Bu kişi benim
Department of Obstetrics and Gynecology, Sakarya Research and Training Hospital, Sakarya, Turkey
Türkiye
Çiğdem Pulatoğlu
Department of Obstetrics and Gynecology, Bayburt Government Hospital, Bayburt, Turkey
Türkiye
Yayımlanma Tarihi
1 Aralık 2017
Gönderilme Tarihi
7 Ekim 2017
Kabul Tarihi
26 Ekim 2017
Yayımlandığı Sayı
Yıl 2017 Cilt: 2 Sayı: 3